These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8471431)

  • 21. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
    Shellard S; Hosking L; Fichtinger-Schepman AM; Hill BT
    Biochem Soc Trans; 1990 Aug; 18(4):622. PubMed ID: 2276474
    [No Abstract]   [Full Text] [Related]  

  • 23. Induction of UV-damage recognition protein by cisplatin treatment.
    Vaisman A; Chaney SG
    Biochemistry; 1995 Jan; 34(1):105-14. PubMed ID: 7819185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
    Maynard KR; Hosking LK; Hill BT
    Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
    Chen G; Zeller WJ; Todorov DK
    Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a novel protein that specifically binds to DNA modified by N-acetoxy-acetylaminofluorene and cis-diamminedichloroplatinum.
    Pietrowska M; Widłak P
    Acta Biochim Pol; 2005; 52(4):867-74. PubMed ID: 15940347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line.
    Nakagawa M; Nomura Y; Kohno K; Ono M; Mizoguchi H; Ogata J; Kuwano M
    J Urol; 1993 Dec; 150(6):1970-3. PubMed ID: 8230547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II).
    Toney JH; Donahue BA; Kellett PJ; Bruhn SL; Essigmann JM; Lippard SJ
    Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8328-32. PubMed ID: 2530581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.
    de Graaf TW; de Jong S; de Vries EG; Mulder NH
    Anticancer Res; 1997; 17(1A):369-75. PubMed ID: 9066679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G; Li Y; Tian F
    Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
    Husain A; He G; Venkatraman ES; Spriggs DR
    Cancer Res; 1998 Mar; 58(6):1120-3. PubMed ID: 9515792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
    Hospers GA; de Vries EG; Mulder NH
    Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
    Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells.
    Chao CC
    Eur J Pharmacol; 1994 Aug; 268(3):347-55. PubMed ID: 7805758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.